In a Nutshell
CJC-1295 and ipamorelin are almost always sold together, and they share a regulatory history: FDA's advisory committee voted against both of them.
- Ipamorelin — PCAC meeting of October 29, 2024. The committee voted against recommending both ipamorelin free base and ipamorelin acetate for the 503A Bulks List 1
- CJC-1295 — PCAC meeting of December 4, 2024. FDA considered five separate forms: free base, acetate, DAC free base, DAC acetate and DAC trifluoroacetate. All five received adverse recommendations, though the count for one form differed from the other four 1
FDA has published official summary minutes for both meetings — these are not trade-reported figures.
Ipamorelin's position is the weaker of the two: it remains in FDA Category 2 — bulk substances that "may present significant safety risks" — under the 503B interim policy, and it also appears on the nominated-but-withdrawn list 3.
FDA has identified specific safety concerns for both — which is notable because for most peptides on this hub the agency's concern is missing data rather than observed events. These are concerns and uncertainties, not established causation:
- Ipamorelin: FDA's review describes a 117-patient trial of intravenous ipamorelin after bowel surgery in which serious adverse events occurred in 17.9% of the ipamorelin arm and 15.5% of placebo, with two deaths in the ipamorelin arm. FDA stated it was unclear whether those deaths were related to ipamorelin 3
- CJC-1295: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited" 3
How the Combination Works
The rationale for pairing them is pharmacologically coherent, and worth understanding rather than dismissing.
CJC-1295 is a GHRH analog — the same class as sermorelin and tesamorelin — acting on the GHRH receptor to stimulate growth hormone release.
"CJC-1295" does not name one product. The prolonged half-life usually attributed to it comes from CJC-1295 with DAC, which binds albumin; free-base and non-DAC forms should not be assumed to share that pharmacology. FDA evaluated five forms separately, and the published human literature does not always identify which was used.
Ipamorelin is a ghrelin receptor agonist — it acts on GHS-R, a different receptor, mimicking ghrelin's growth-hormone-releasing action. Its claimed advantage over older growth hormone-releasing peptides is greater selectivity, with minimal effect on cortisol and prolactin.
Because they act on two different receptors, combining them can produce a larger growth hormone release than either alone. That is the pitch.
Why "More Growth Hormone" Isn't Automatically Better
The combination's selling point is a bigger hormone release, and two things are worth saying about that.
A larger release is not automatically a better outcome. The effects associated with growth hormone excess — fluid retention, joint pain, carpal-tunnel-type symptoms, reduced insulin sensitivity — are dose-related. The more moderate, pituitary-mediated response of a single GHRH analog is a feature of that design, not a shortfall — though it does not guarantee levels stay within range either.
The comparison has not been made properly. No controlled human trial has compared this combination against a single agent on outcomes that matter — body composition, sleep quality, function. Serum growth hormone levels are a biomarker, and an effect on a biomarker is not an effect on a patient.
CJC-1295 DAC's extended half-life is double-edged, though not in the way it is usually described. Short-term human studies found prolonged increases in mean and trough GH and IGF-1 while preserving GH pulsatility — it does not replace pulses with continuous release. The real question is whether prolonged elevation of baseline exposure produces clinically useful outcomes, or acceptable long-term risk. Neither has been established.
What the Evidence Shows
Evidence tier: C.
| Claim commonly made | What the evidence supports |
|---|---|
| Increases growth hormone levels | Supported — this is the mechanism |
| Improves body composition | No controlled human trial evidence for the combination |
| Improves recovery and sleep | Anecdotal; not established in controlled trials |
| Anti-aging effects | Not supported |
| Safer than HGH | Mechanistically preserves some feedback, but ipamorelin's Category 2 designation and FDA's adverse-event citations complicate this framing |
Safety and What Is Known
Unusually for this hub, the concern here is not only missing data:
- Ipamorelin: serious adverse events including two deaths occurred in a 117-patient IV postoperative trial, at rates of 17.9% versus 15.5% on placebo, and FDA stated causality for the deaths was unclear 3. That is a different route and clinical context from subcutaneous use, and it does not establish that ipamorelin caused those outcomes — but combined with the absence of adequate subcutaneous safety data, FDA treated it as grounds for concern
- CJC-1295: FDA reported increased heart rate and systemic vasodilatory reactions in short-term human studies involving CJC-1295 DAC or incompletely specified material 3. Products marketed as "CJC-1295" are not necessarily equivalent, so this should not be attributed indiscriminately to every form
- Characterization: ipamorelin contains unnatural amino acids, which FDA notes adds to the complexity of confirming what a preparation contains 3
- Immunogenicity: aggregation and peptide-related impurities, FDA's standard concern across this class
- Insulin sensitivity: as with any growth hormone secretagogue, relevant if you have diabetes or prediabetes
- Product risk: most in circulation is research-grade — see peptide sourcing and quality
- Pregnancy and breastfeeding: no data; not appropriate
Red Flags — Seek Care Now
- Palpitations with chest pain, fainting, severe breathlessness or other concerning symptoms — seek urgent care, and tell the treating clinician the exact product and form used
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Persistent headaches, visual changes, or swelling of hands and feet
- Symptoms of high blood sugar
- Fever, spreading redness, swelling or pus at an injection site
Tell any treating clinician what you have used.
Prohibited in Sport
Growth hormone secretagogues, including CJC-1295 and ipamorelin, are prohibited under World Anti-Doping Agency rules and by organizations following them. This applies regardless of prescription status. Confirm with your governing body directly.
On Dosing
This page does not provide dosing protocols. Short-term human pharmacology studies of CJC-1295 DAC exist, but no validated dosing regimen for the marketed CJC-1295/ipamorelin combination has been established through controlled clinical-outcome studies — and circulating protocols are applied to products of unverified concentration and form.
What You Can Do About It
If the goal is body composition, recovery or sleep, each has an assessment pathway. Body composition responds to measurable inputs — protein intake, resistance training, sleep quality, thyroid function, testosterone status. Getting those identified and addressed is the better-evidenced route than optimizing a hormonal pathway that may not be the constraint.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning, repeated at visits. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get CJC-1295 or ipamorelin on prescription?
Neither CJC-1295 nor ipamorelin is an FDA-approved drug. Both were voted against by FDA's advisory committee in 2024, and ipamorelin remains in FDA Category 2.
Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.
Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Sermorelin vs Ipamorelin — the direct comparison
- Sermorelin — mechanism, evidence and current regulatory status
- Sermorelin vs HGH
- Are Peptides Legal in the US? — Category 2 and the bulks list explained
- The Downsides of Peptide Therapy
Frequently Asked Questions
What is CJC-1295 ipamorelin good for?
It is marketed for growth hormone support, recovery, body composition and sleep, pairing a GHRH analog with a ghrelin receptor agonist to stimulate two receptors. Neither component is FDA-approved, FDA's advisory committee voted against both in 2024, and there is no controlled human trial evidence for the combination on outcomes that matter.
Is CJC-1295 ipamorelin FDA approved?
No. Ipamorelin was voted against by FDA's advisory committee on October 29, 2024 and CJC-1295 on December 4, 2024. Ipamorelin additionally remains in FDA Category 2 — substances that may present significant safety risks — under the 503B interim policy.
Does CJC ipamorelin affect testosterone?
They act on the growth hormone axis rather than directly on testosterone production. Indirect effects via body composition change are plausible but not established in controlled trials. If low testosterone is the actual concern, it is measurable — see low testosterone care.
How long does it take to see results from CJC-1295 and ipamorelin?
There is no evidence-based answer, because no controlled human trial has measured meaningful outcomes over time. Timelines circulating online are anecdotal.
Does ipamorelin increase appetite?
It may. Ipamorelin acts on the ghrelin receptor, and ghrelin is centrally involved in appetite signaling — relevant if body composition is the goal.
Is CJC-1295 ipamorelin safe?
FDA has identified concerns for both: serious adverse events including two deaths in a 117-patient trial of intravenous ipamorelin after bowel surgery — where serious-event rates were 17.9% on ipamorelin versus 15.5% on placebo, and FDA stated causality for the deaths was unclear — and increased heart rate and systemic vasodilatory reactions in studies of CJC-1295 DAC or incompletely specified material. These are regulatory concerns, not established causation.
References
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, "Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024," [Online]. Available: https://www.fda.gov/media/185412/download [Accessed: Oct. 5, 2026]. (Ipamorelin briefing document: https://www.fda.gov/media/182088/download; PM transcript, Topic 3 Ipamorelin: https://www.fda.gov/media/185414/download.) ↩
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, "Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024," [Online]. Available: https://www.fda.gov/media/185642/download [Accessed: Oct. 5, 2026]. (CJC-1295 briefing document: https://www.fda.gov/media/183819/download; AM transcript: https://www.fda.gov/media/185641/download.) ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- D. E. Beck, W. B. Sweeney, M. D. McCarter; Ipamorelin 201 Study Group, "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," International Journal of Colorectal Disease, vol. 29, no. 12, pp. 1527-1534, Dec. 2014, [Online]. Available: https://doi.org/10.1007/s00384-014-2030-8. PMID: 25331030. [Accessed: Oct. 5, 2026]. ↩
- C. Dieguez, M. López, F. Casanueva, "Hypothalamic GHRH," Reviews in Endocrine and Metabolic Disorders, vol. 26, pp. 297-303, Jun. 2025, [Online]. Available: https://doi.org/10.1007/s11154-025-09951-y. PMID: 39913072. PMCID: PMC12137398. [Accessed: Jul. 26, 2026]. ↩
- M. Ionescu, L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog," The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 12, pp. 4792-4797, Dec. 2006, [Online]. Available: https://doi.org/10.1210/jc.2006-1702. PMID: 17018654. [Accessed: Oct. 5, 2026]. ↩
- World Anti-Doping Agency, "The 2026 Prohibited List — World Anti-Doping Code International Standard," effective Jan. 1, 2026, §S2.2.4 Growth hormone releasing factors. [Online]. Available: https://www.wada-ama.org/en/prohibited-list [Accessed: Oct. 5, 2026]. ↩